OVERVIEW
A Phase 1b Randomized, Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-8588 in People With HIV-1 Who are Virologically Suppressed on Antiretroviral Therapy
PROTOCOL SUMMARY
The primary objective of this study was to learn how safe and tolerable, single and multiple doses of GS-8588 were in participants with well-controlled HIV-1.
Participation requirements
Age
18 years +
Sex
All
Healthy Volunteers
No
Study details
Medical Condition
HIV-1
Gender
N/A
Date
May 2022 - August 2025
Study Type
Interventional
Study Phase
Phase 1b
Product
Amtabafusp Alfa (GS-8588)
Join Gilead Trial Connect and help advance clinical research. Your participation is key to developing future treatments.
Share Trial